ResearcherHokkaido UniversityActive in the last 2 years
Ryodai Yamamura
Matched on ORCID iD 0000-0002-9342-7702; OpenAlex author ID A5031245754. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers
Papers 5
- Genotype-Informed Whole-Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC. Co-author DOI 10.1111/cas.70522↗
- Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC Co-author DOI 10.64898/2026.03.16.711738↗
- Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ymthe.2025.05.037↗
- Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.16100↗
- Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-22-3762↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Masahiro Sonoshita · 5 shared papers, 2023–2026 · strength 1.02
- Paper Genotype-Informed Whole-Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC. DOI 10.1111/cas.70522↗
- Paper Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma. DOI 10.1016/j.ymthe.2025.05.037↗
- Paper Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC DOI 10.64898/2026.03.16.711738↗
- Takako Ooshio · 4 shared papers, 2023–2026 · strength 0.84
- Paper Genotype-Informed Whole-Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC. DOI 10.1111/cas.70522↗
- Paper Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma. DOI 10.1016/j.ymthe.2025.05.037↗
- Paper Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma. DOI 10.1111/cas.16100↗
- Sho Sekiya · 3 shared papers, 2023–2026 · strength 0.52
- Paper Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC DOI 10.64898/2026.03.16.711738↗
- Paper Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma. DOI 10.1111/cas.16100↗
- Paper Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocar… DOI 10.1158/0008-5472.can-22-3762↗
- Junki Fukuda · 3 shared papers, 2023–2026 · strength 0.52
- Paper Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC DOI 10.64898/2026.03.16.711738↗
- Paper Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma. DOI 10.1111/cas.16100↗
- Paper Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocar… DOI 10.1158/0008-5472.can-22-3762↗
- Satoshi Hirano · 3 shared papers, 2023–2026 · strength 0.52
- Paper Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC DOI 10.64898/2026.03.16.711738↗
- Paper Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma. DOI 10.1111/cas.16100↗
- Paper Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocar… DOI 10.1158/0008-5472.can-22-3762↗
- Han Hai · 2 shared papers, 2025–2026 · strength 0.50
- Hui Jiang · 2 shared papers, 2025–2026 · strength 0.50
- Toru Nakamura · 2 shared papers, 2023–2024 · strength 0.34
- Shintaro Takeuchi · 1 shared paper, 2026 · strength 0.18
- Kazuaki Harada · 1 shared paper, 2026 · strength 0.18
- Masaki Kuwatani · 1 shared paper, 2026 · strength 0.18
- Toshimichi Asano · 1 shared paper, 2026 · strength 0.18
- Yasuyuki Kawamoto · 1 shared paper, 2026 · strength 0.18
- Kazumichi Kawakubo · 1 shared paper, 2026 · strength 0.18
- Atsushi Enomoto · 1 shared paper, 2026 · strength 0.18
- Atsushi Masamune · 1 shared paper, 2026 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.